Protara reports positive TARA-002 NMIBC data; expects key milestones in 2025; cash runway into 2027

Protara Therapeutics, Inc.

TARA-002 in NMIBC: 72% CR at six months, 70% at any time; 100% maintained CR from 3 to 6 months; no Grade 2+ TRAEs.
Expects 12-month evaluable data mid-2025 and futility analysis of ~25 BCG-unresponsive patients by end 2025.
Expects to start THRIVE-3 registrational trial of IV Choline Chloride in 1H 2025; FDA Fast Track granted.
TARA-002 in LMs: initial results from additional STARBORN-1 cohorts expected by end of 1H 2025.
Cash of $81.5M plus ~$100M gross from December offering (including partial option exercise) funds operations into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.